GSPT1 DAC

GSPT1 DAC is a Degrader Antibody Conjugate (TPD-ADC) program developed by Almac Discovery that combines the high specificity of monoclonal antibodies with the potent cell-killing mechanism of molecular glue degraders. The therapeutic approach targets G1 to S phase transition 1 (GSPT1) and GSPT2, which are essential translation termination factors; their targeted degradation leads to cell cycle arrest and apoptosis. The DAC platform utilizes antibodies directed against either Human Epidermal Growth Factor Receptor 2 (HER2) for the treatment of HER2-positive solid tumors, such as breast and gastric cancers, or CD33 for the treatment of acute myeloid leukemia (AML) and other CD33-positive haematological malignancies. By delivering the molecular glue payload directly to tumor cells, this modality aims to enhance the therapeutic window and reduce the systemic toxicities often associated with non-targeted GSPT1 degradation.